Toggle light / dark theme

The University of Chicago Medicine is among the first 30 institutions in the country to offer tumor-infiltrating lymphocyte (TIL) therapy for advanced melanoma, immediately activating as an authorized treatment center after federal regulators approved the treatment on February 16, 2024.

TILs are…


Some patients with advanced melanomas — those that can’t be surgically removed or have spread to other parts of the body — don’t respond to standard treatment options such as immunotherapies and targeted therapies. TIL therapy gives these patients another therapeutic option: a completely personalized treatment made from the patient’s own cells that needs to be administered only once, since the cells remain in the body and keep performing their tumor-attacking duties.

Other cell therapies, such as CAR T-cell therapies, are currently approved only for blood cancers like leukemia. TIL therapy, which showed promising results in clinical trials, is the first FDA-approved cell therapy to treat solid tumors.

science images
This year, Rockefeller scientists plumbed the depths of wound repair and tackled how songbirds solve problems; they used microchips to grow mini-lungs and proposed an environmental trigger for multiple sclerosis. Efforts to combat COVID, Hepatitis B, and other infections bore fruit, and countless papers shed light on basic research, answering questions that have long baffled biologists. Here are some of the intriguing discoveries that came out of Rockefeller in 2023.

Old sperm, new mutations

As the male reproductive system ages, it becomes more and more susceptible to mutations. New research from the laboratory of Li Zhao explored this phenomenon in fruit flies, by focusing on how mutations arise during the formation of sperm. The team found that, while mutations are common in the testes of both young and old flies, the repair mechanisms that remove those mutations and maintain genomic integrity during spermatogenesis become less efficient in older individuals, leading to the accumulation and persistence of more mutations in older flies.

Computing has already accelerated scientific discovery. Now scientists say a combination of advanced AI with next-generation cloud computing is turbocharging the pace of discovery to speeds unimaginable just a few years ago.

Microsoft and the Pacific Northwest National Laboratory (PNNL) in Richland, Washington, are collaborating to demonstrate how this acceleration can benefit chemistry and materials science – two scientific fields pivotal to finding energy solutions that the world needs.

Scientists at PNNL are testing a new battery material that was found in a matter of weeks, not years, as part of the collaboration with Microsoft to use to advanced AI and high-performance computing (HPC), a type of cloud-based computing that combines large numbers of computers to solve complex scientific and mathematical tasks.

Microsoft presents LLMs in the Imaginarium.

Tool Learning through Simulated Trial and Error https://huggingface.co/papers/2403.

Tools are essential for large language models (LLMs) to acquire up-to-date information and take consequential actions in external environments.


Join the discussion on this paper page.

Chatbot Arena.

An open platform for evaluating llms by human preference.

Large Language Models (LLMs) have unlocked new capabilities and applications; however, evaluating the alignment with human preferences still poses significant challenges.


Join the discussion on this paper page.

The Rebellionaire Road Rally has made its way down to Austin, TX. This time we’re joined by Farzad (@farzyness) to test out Tesla FSD v12 on the streets of the greater Austin area. This is part 2 of the journey with Farzad joining in the car adding helpful commentary.

#Tesla #rebellionaire.

Rebellionaires check out www.Rebellionaire.com.
Rebellionaire is a brand of Halter Ferguson Financial. www.hffinancial.com/disclaimer.

As of March 7th, 2024, clients and employees of our firm Halter Ferguson Financial own Tesla stock and/or options and thereby stand to materially benefit from a rise in the share price. Past performance is no assurance of future results. Halter Ferguson Financial, Inc. (“Halter Ferguson Financial”) is a registered investment adviser with its principal place of business in the State of Indiana. A complete list of all recommendations will be provided if requested for the preceding period of not less than one year. It should not be assumed that recommendations made in the future will be profitable or will equal the performance of the securities in this list. Opinions expressed are those of Halter Ferguson Financial, Inc. and are subject to change, not guaranteed and should not be considered recommendations to buy or sell any security.